Analysts Set Simulations Plus, Inc. (NASDAQ:SLP) Price Target at $24.40

Simulations Plus, Inc. (NASDAQ:SLP) has been assigned an average recommendation of “Hold” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $24.40.

A number of research analysts recently commented on the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Tuesday, July 15th. Cowen assumed coverage on shares of Simulations Plus in a report on Tuesday, September 30th. They set a “hold” rating for the company. Citigroup reaffirmed a “market perform” rating on shares of Simulations Plus in a report on Tuesday, October 28th. Stephens cut their price objective on shares of Simulations Plus from $28.00 to $20.00 and set an “overweight” rating on the stock in a research report on Tuesday, July 15th. Finally, TD Cowen began coverage on shares of Simulations Plus in a research report on Tuesday, September 30th. They issued a “hold” rating and a $16.00 target price for the company.

Simulations Plus Trading Down 3.3%

NASDAQ:SLP opened at $17.13 on Monday. The stock has a 50 day moving average of $15.75 and a 200-day moving average of $19.58. The firm has a market capitalization of $344.78 million, a PE ratio of -5.44 and a beta of 0.98. Simulations Plus has a 52 week low of $12.39 and a 52 week high of $37.67.

Institutional Trading of Simulations Plus

Several large investors have recently added to or reduced their stakes in the business. Tributary Capital Management LLC lifted its holdings in Simulations Plus by 214.7% in the 3rd quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock valued at $17,134,000 after acquiring an additional 775,704 shares during the last quarter. First Light Asset Management LLC acquired a new position in shares of Simulations Plus in the 2nd quarter worth approximately $6,232,000. Stephens Investment Management Group LLC bought a new stake in shares of Simulations Plus in the 2nd quarter worth approximately $4,687,000. Herald Investment Management Ltd bought a new stake in shares of Simulations Plus in the 3rd quarter worth approximately $3,016,000. Finally, Ameriprise Financial Inc. lifted its stake in Simulations Plus by 25.3% during the second quarter. Ameriprise Financial Inc. now owns 875,447 shares of the technology company’s stock valued at $15,277,000 after purchasing an additional 176,747 shares during the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.